Relationships between SUVmax of lung adenocarcinoma and different T stages, histological grades and pathological subtypes: a retrospective cohort study in China

Xiaoyan Sun, Tianxiang Chen, Chun Xie, Liu Liu, Bei Lei, Lihua Wang, Maomei Ruan, Hui Yan, Qi Zhang, Cheng Chang, Wenhuixie

ABSTRACT

Objectives Cancer cell has aberrant metabolism. The purpose of this study aimed to investigate relationships between maximum standard uptake value (SUVmax) of 18fluoro-2-deoxy-d-glucose and T stages, histological grades and pathological subtypes of lung adenocarcinoma.

Design Retrospective cohort study, employing the Kruskal-Wallis, Bonferroni-Dunn and Mann-Whitney tests to compare SUVmax of different T stages, histological grades and pathological subtypes of lung adenocarcinoma.

Setting The outpatient who had aberrant positron emission tomography/CT (PET/CT) images in chest were enrolled this study from August 2016 to November 2018 in Shanghai, China.

Participants Initial 11270 patients with suspected lung cancer who underwent PET/CT examinations were surveyed. A total of 1454 patients who were diagnosed as lung adenocarcinoma by pathologist were included in this project.

Primary outcome measures SUVmax value at different tumour-node-metastasis stages of lung adenocarcinoma before surgery.

Results The mean SUVmax of patients with lung adenocarcinoma was significantly elevated with the increase in T stages. There were significant evident differences in SUVmax among T1a–T1c (p<0.05). However, after the staging of patients was more than T1 stage, SUVmax of T2a, T2b, T2 visceral pleural invasion, T3 and T4 had no dramatic changes. SUVmax value of lung adenocarcinoma in the same T stage group was the highest in patients with the high grade of malignancy and solid-predominant invasive adenocarcinoma.

Conclusions SUVmax value was significantly associated with T stages, grades of malignancy and pathological subtypes of lung adenocarcinoma.

INTRODUCTION

Lung cancer is a highly heterogeneous tumour, which is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) based on pathological features. This classification can stratify the malignant grades of tumour and guide therapy or prognosis.1–6 Maximum standard uptake value (SUVmax), as a metabolic parameter of 18fluoro-2-deoxy-d-glucose (18-FDG) positron emission tomography-CT (PET/CT), is so far the most reflective of malignant tumour. The detection of SUVmax has been shown to be positively correlated with the tumour-node-metastasis (TNM) staging of lung adenocarcinoma.7 Therefore, it was widely studied in predicting prognosis of lung adenocarcinoma.8–12 Our previous study showed that SUVmax of patients can predict the histological grades of cancer using the receiver operating characteristic curve to find the cut-off value of low, medium and high histological grades of lung adenocarcinoma.13

Current lung cancer TNM staging system is mainly used to describe the growth and metastasis pattern of lung cancer, which has an important guiding role for clinical treatment and prognosis judgement. Studies showed that the size of lung adenocarcinoma was relevant to SUVmax.14–16 However, there is no clear conclusion about the relationship between T staging and SUVmax. Therefore, the study of the relationship between
SUVmax and different T stages as well as histological grades of tumours is also a potential new direction for the application of PET/CT in the field of lung cancer.

The purpose of our study was to explore the relationship between SUVmax and T stages, histological grades and pathological subtypes of lung adenocarcinoma.

MATERIALS AND METHODS

Patients' study population and inclusion criteria
We retrospectively analysed 11,270 patients with suspected lung cancer who underwent PET/CT examinations in our hospital from August 2016 to November 2018. From these patients, 1,454 patients were pathologically confirmed as lung adenocarcinoma by two special pathologists after surgery. The diagnosed cases were based on the criteria recommended by the international association for the study of lung cancer. T stages, grades and subtypes of lung carcinoma were categorised according to tumour growth pattern, pathological diagnosis of resection specimens or biopsy and whole body PET/CT images. Another 9,816 cases were excluded because of the following reasons: non-lung cancer, unclear pathological subtypes and tumour boundary, other malignant tumours.

Measurement of SUVmax
The PET-CT (Siemens Biograph 64) results were reviewed by two attending nuclear medicine physicians. SUVmax values were obtained using attenuation-corrected transaxial images, the injected doses of 18-FDG, the patient's body weight and the cross-calibration factor between PET and the dose calibrator. SUVmax was defined as the highest value of interest in the primary lung tumour of each patient.

Table 1 Baseline characteristics of the study cohort and each T stage group of the 1454 patients with lung adenocarcinoma

| Characteristic                  | Sample size | T1 | T2 | T3 | T4 | P value |
|--------------------------------|-------------|----|----|----|----|---------|
| Total number                   | 1454        | 977| 410| 47 | 20 |         |
| Age, yr, mean±SD               | 61.22±9.65  | 60.69±9.71| 62.20±9.59| 63.02±8.19| 60.95±9.87| 0.099 |
| Sex, n (%)                     |             |    |    |    |    | <0.001 |
| Male n (%)                     | 610 (41.95%)| 375 (38.40%)| 193 (47.07%)| 32 (68.09%)| 11 (55%)|        |
| Female n (%)                   | 844 (58.05%)| 602 (61.60%)| 217 (52.93%)| 15 (31.91%)| 9 (45%)|        |
| Smoking history, n(%)          | 486 (33.42%)| 292 (30.05%)| 157 (38.05%)| 27 (57.45%)| 10 (50%)| <0.001 |
| Male, n (%)                    | 951 (65.41%)| 671 (74.37%)| 250 (79.27%)| 20 (42.55%)| 10 (50%)|        |
| Female, n (%)                  | 17 (1.17%)  | 14 (1.43%)  | 3 (1.38%)  | 0  | 0  |        |
| Family history of malignancy, n (%)| 452 (31.09%)| 325 (33.26%)| 113 (27.56%)| 11 (23.40%)| 7 (35%)| 0.217 |
| Male, n (%)                    | 205 (33.61%)| 133 (35.38%)| 60 (31.09%) | 9 (28.12%)| 4 (36.36%)|        |
| Female, n (%)                  | 247 (29.27%)| 192 (31.94%)| 53 (24.42%) | 2 (13.33%)| 3 (33.33%)|        |
| Mass location, n (%)           |             |    |    |    |    | 0.23   |
| Upper right, n (%)             | 513 (35.28%)| 349 (35.72%)| 141 (34.39%)| 19 (40.43%)| 4 (20%)|        |
| Middle right, n (%)            | 99 (6.81%)  | 74 (7.59%)  | 22 (5.37%) | 3 (6.38%) | 0  |        |
| Low right, n (%)               | 250 (17.19%)| 166 (17.01%)| 69 (16.83%) | 11 (23.40%)| 4 (20%)|        |
| Upper left, n (%)              | 392 (26.96%)| 263 (26.95%)| 112 (27.32%)| 9 (19.15%)| 8 (40%)|        |
| Left lower, n (%)              | 200 (13.76%)| 124 (12.73%)| 66 (16.09%) | 5 (10.64%)| 4 (20%)|        |
| N stage                        |             |    |    |    |    | <0.001 |
| NX                             | 17 (1.20%)  | 10 (1.07%) | 7 (1.71%)  | 0  | 0  |        |
| N0                             | 1200 (82.51%)| 897 (91.9%) | 273 (66.59%)| 23 (48.94%)| 10 (50%)|        |
| N1                             | 154 (10.62%)| 46 (4.71%)  | 92 (22.44%)| 13 (27.66%)| 1 (5%) |        |
| N2                             | 77 (5.31%)  | 22 (2.25%)  | 36 (8.78%) | 9 (19.15%)| 9 (45%)|        |
| N3                             | 5 (0.35%)   | 1 (0.11%)  | 2 (0.48%)  | 2 (4.25%) | 0  |        |

n, case number; N, node; T, tumour; yrs, years.
adenocarcinoma (LPA), acinar-predominant invasive adenocarcinoma (APA), papillary predominant invasive adenocarcinoma (PPA), micropapillary-predominant invasive adenocarcinoma (MPA), and solid-predominant invasive adenocarcinoma (SPA). The subtypes were divided into low grade (AIS, MIA and LPA), intermediate grade (APA and PPA) and high grade (MPA and SPA).

### Statistical analysis
Continuous variables with a normal distribution (age, weight and SUVmax) were expressed as mean±SD. Use one-way analysis of variance to analyse the distribution of all variables. \( \chi^2 \) test, Student’s t test and non-parametric Wilcoxon rank sum test were used to compare the clinical characteristics of each group. The Kruskal-Wallis, Bonferroni-Dunn and Mann-Whitney tests were used to compare the differences and perform univariate analysis on the continuous values between the groups. SPSS V.20.0 (IBM, Armonk, New York) was used for data analysis. \( p<0.05 \) is considered statistically significant.

### Patient and public involvement
No patients were involved in the design and reporting of this study.

### RESULTS

#### Patient demographic and baseline characteristics

The clinical characteristics of 1454 patients are shown in Table 1. The average age of the patients was 61.22±9.65 years old. Among these patients, there were significant differences in gender, smoking history and N stages. Women were more than that of men (58.05% vs 41.95%, \( p<0.001 \)). Patients with smoking history were significantly more than those non-smokers (66.58% vs 33.42%, \( p<0.001 \)). The majority of smokers were men (98.2% vs 1.8%, \( p<0.001 \)). The number of patients with T1 stage lung adenocarcinoma was the largest population with 977 patients (67.19%). The number of lung adenocarcinomas from T2 to T4 decreased successively and was 410 cases (28.20%), 47 cases (3.23%) and 20 cases (1.38%), respectively. Among enrolled cases, T1 stage group contained all pathological subtypes except MPA subtype. The T2 stage group contained five pathological subtypes: LPA, APA, PPA, MPA and SPA.

### Table 2: P value tables of Tn and Tnx staging groups after lung adenocarcinoma was grouped according to histological grades and pathological subtypes

| Classification                | T1 | T2 | T3 | T4 | T1a | T1b | T1c | T2a | T2b | T2c |
|------------------------------|----|----|----|----|-----|-----|-----|-----|-----|-----|
| Kruskal-Wallis test          |    |    |    |    |     |     |     |     |     |     |
| Histological grade           | <0.001 | <0.001 | /  | /  | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.149* |
| Pathological subtype         | <0.001 | <0.001 | 0.032 | 0.188 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.019 |
| Bonferroni-Dunn test         |    |    |    |    |     |     |     |     |     |     |
| Low–intermediate grade group | <0.001 | 0.027 | /  | /  | <0.001 | <0.001 | <0.001 | 0.149 | 0.728 | /    |
| Low–high grade group         | <0.001 | <0.001 | /  | /  | 0.002 | <0.001 | <0.001 | 0.001 | 0.063 | /    |
| Intermediate–high grade group| <0.001* | <0.001 | 0.007* | 0.049* | 0.278 | <0.001 | <0.001 | <0.001 | 0.004 | /    |

Tn, tumour staging was divided into groups including T1 (≤3 cm), T2 (>3,≤5 cm), T3 (>5,≤7), T4 (>7 cm) a. The above is abbreviated as Tn (n=1–4); Tnx (Tnx, n=1, 2, x=a, b, c, VPI).

VPI, visceral pleural invasion.
APA, PPA, MPA and SPA. Both T3 and T4 stage groups included four subtypes: APA, PPA, MPA and SPA.

Analysis of the relationship between SUVmax and T staging of lung adenocarcinoma

Relationship of SUVmax in Tn staging groups of lung adenocarcinoma is shown in figure 1. The mean SUVmax of patients with lung adenocarcinoma of T1–T4 stage increased with the increase in T stages (T1<T2<T3<T4). There were statistical differences in SUVmax of the four T stage groups (Kruskal-Wallis test, p<0.001, table 2).

After pairwise comparison, it was found that there were significant differences between T1 and T2–4 (p<0.001), but the differences among T2–4 stages were not significant (table 2, Bonferroni-Dunn correction test, p>0.05) (figure 1).

We also compared SUVmax of different histological grades and pathological subtype groups in the same T stage group. The results are shown in table 2. T1 and T2 were divided into low, medium and high-grade groups. T3 and T4 were divided into medium and high-grade groups. The median SUVmax followed the rule of low-medium-high grade groups. There was a difference in SUVmax value between the middle and high-level groups in the T3 and T4 groups, and the middle level < high level (Mann-Whitney test, p<0.05). According to Kruskal-Wallis test, except T4 (p=0.188), there were differences in SUVmax values of each pathological subtype group contained in each (any) Tn and Tnx stage groups (T3, p=0.032; others) p<0.001).

We further evaluated the relationship between SUVmax of different Tn stage groups and histological grades (table 3). SUVmax value of the same histological grade or the same pathological subtype group increases with the increase in T stages, and the difference was statistically significant. After pairwise comparison, there were significant differences in SUVmax between T1 and T2–4 of lung adenocarcinoma groups, but there were no significant differences among T2–4 groups.

The relationship between SUVmax of each Tnx subtype group of T1 and T2 lung adenocarcinoma and histological grade or pathological subtype

Since it was found that there were significant different SUVmax values between T1 stage and T2 stage, we further evaluated the relationship between SUVmax and Tn subtypes. Figure 2 shows comparison of SUVmax among

| Classification | Total | L | I | H | AIS | MIA | LPA | APA | PPA | MPA | SPA |
|----------------|-------|---|---|---|-----|-----|-----|-----|-----|-----|-----|
| Kruskal-Wallis *(P value)* | | | | | | | | | | | |
| T1–T4 | p<0.001* | p<0.001* (T1–2) | p<0.001* | / | / | 0.001*(T1-2) | p<0.001 | p<0.001 | 0.031 | p<0.001 |
| T1a–T2b | p<0.001* | p<0.001* | p<0.001* | 0.738* (T1a-T1b) | 0.014* (T1a-T1b) | p<0.001 | p<0.001 | p<0.001 | 0.048 | p<0.001 |
| Bonferroni-Dunn test(P value) | | | | | | | | | | | |
| T1–T2 | p<0.001 | / | p<0.001 | 0.01 | / | / | 0.001 | p<0.001 | p<0.001 | 0.078 | 0.019 |
| T1–T3 | p<0.001 | / | p<0.001 | p<0.001 | / | / | / | p<0.001 | 0.008 | 0.290 | 0.002 |
| T1–T4 | p<0.001 | / | p<0.001 | 0.00 | / | / | / | 0.005 | 0.034 | 0.822 | 0.112 |
| T2–T3 | 0.900 | / | 0.741 | 0.614 | / | / | / | 1.000 | 1.000 | 1.000 | 1.000 |
| T2–T4 | 0.249 | / | 0.624 | 0.994 | / | / | / | 0.932 | 1.000 | 1.000 | 0.566 |
| T3–T4 | 1.000 | / | 1.000 | 1.000 | / | / | / | 1.000 | 1.000 | 1.000 | 1.000 |
| **Tn, tumour staging was divided into groups including T1 (≤3 cm), T2 (>3,≤5 cm), T3 (>5,≤7), T4 (>7 cm) a. The above is abbreviated as Tn (n=1–4); Tnx (Tnx, n=1, 2, x=a, b, c, VPI).**

AIS, adenocarcinoma in situ; APA, acinar-predominant invasive adenocarcinoma; H, high grade group; I, intermediate grade group; L, low grade group; LPA, lepidic-predominant invasive adenocarcinoma; MIA, minimally invasive adenocarcinoma; MPA, micropapillary-predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid-predominant invasive adenocarcinoma; VPI, visceral pleural invasion.


Table 4  
P value table of histological grade group and pathological subtype group after grouping according to Tn and Tnx stages of lung adenocarcinoma

| Classification | Totle | The low-grade group | The intermediate-grade group | The high-grade group | LPA | APA | PPA | MPA | SPA |
|---------------|-------|---------------------|------------------------------|---------------------|-----|-----|-----|-----|-----|
| Bonferroni-Dunn test (P value) |       |                     |                              |                     |     |     |     |     |     |
| T1a–T1b       | p<0.001* | 0.102              | p<0.001*                     | 1.000               | 0.192| 0.003* |0.180 | /   | 1.000 |
| T1a–T1c       | p<0.001* | p<0.001*           | 0.189                       | 0.012*              | p<0.001* | p<0.001* | / | 0.100 |
| T1a–T2a       | p<0.001* | 0.002*             | 0.064                       | 0.006*              | p<0.001* | p<0.001* | / | 0.044* |
| T1a–T2b       | p<0.001* | 0.048*             | 0.025*                      | 0.017*              | p<0.001* | p<0.001* | / | 0.032* |
| T1a–T2VPI     | p<0.001 | /                   | 0.342                       | /                   | p<0.001 | p<0.001* | / | 0.366 |
| T1b–T1c       | p<0.001 | 0.028               | 0.001                       | 0.793               | p<0.001 | 0.014 | 1.000 | 0.002 |
| T1b–T1a       | p<0.001 | 0.055               | p<0.001                     | 0.228               | p<0.001 | p<0.001 | 0.151 | p<0.001 |
| T1b–T2b       | p<0.001 | 0.270               | p<0.001                     | 0.279               | p<0.001 | p<0.001 | 0.074 | 0.001 |
| T1b–T2VPI     | p<0.001 | /                   | 0.045                       | /                   | p<0.001 | p<0.001 | 1.000 | 0.215 |
| T1c–T2a       | p<0.001 | 1.000               | p<0.001                     | 1.000               | 1.000 | 0.002 | 0.030 | 1.000 | 1.000 |
| T1c–T2b       | p<0.001 | 1.000               | 0.003                       | 1.000               | 1.000 | 0.111 | 0.072 | 0.965 | 1.000 |
| T1c–T2VPI     | p<0.001 | /                   | 1.000                       | /                   | p<0.001 | 0.037 | 1.000 | 1.000 |
| T2a–T2b       | 1.000   | 1.000               | 1.000                       | 1.000               | 1.000 | 1.000 | 1.000 | 1.000 |
| T2a–T2VPI     | 0.901   | 0.233               | 1.000                       | /                   | 0.055 | 1.000 | 1.000 | 1.000 |
| T2b–T2VPI     | 1.000   | 1.000               | 0.723                       | /                   | 1.000 | 1.000 | 1.000 | 1.000 |

Tn, tumour staging was divided into groups including T1 (<3 cm), T2 (>3,≤5 cm), T3 (>5,≤7), T4 (>7 cm) a. The above is abbreviated as Tn (n=1–4); Tnx (Tnx, n=1, 2, 3, 4, a, b, c, VPI).

The italics indicate a significant difference in P values.

APA, acinar-predominant invasive adenocarcinoma; H, high grade group; I, intermediate grade group; L, low grade group; LPA, lepidic-predominant invasive adenocarcinoma; MPA, micropapillary-predominant invasive adenocarcinoma; PPA, papillary predominant invasive adenocarcinoma; SPA, solid-predominant invasive adenocarcinoma; VPI, visceral pleural invasion.

the same Tnx staging group. SUVmax values of T stage subgroups from T1a to T2b also followed the increasing law (T1a–T1b→T1c→T2a–T2VPI→T2b). SUVmax value of the same histological grade or the same pathological subtype group increases with the increase in Tnx stage, and the difference is statistically significant (see table 4 for p value). AIS and MIA did not include in this table because AIS and MIA only are minimal local tumour. Pairwise comparison of SUVmax values of each group showed differences among T1a–T1b, T1b–T1c and T1c–T11c were statistically significant (Bonferroni-Dunn correction test, p<0.001). However, no significant differences among T2a–T2b, T2a–T2VPI and T2b–T2VPI were found (Bonferroni-Dunn calibration test, p>0.05, figure 2). Comparing the T1x group with the T2x group, comparing T1a, T1b and T1c with T2a, T2 VPI and T2b, respectively, the difference in SUVmax value of each group was statistically significant (Bonferroni-Dunn-adjusted test, p<0.001).

DISCUSSION

This study revealed that SUVmax value of lung adenocarcinoma was associated with T stages. When lung adenocarcinoma was at stage T1, SUVmax values of different size lung adenocarcinoma (T1x) groups were significantly different, but when the lung adenocarcinoma stage was more than T1 stage, the mean SUVmax of the T2VPI group was higher than that of the T1 stage. The APA subtypes in the T2VPI group showed higher FDG uptake compared with the APA subtypes of other T stage groups.

Previous studies have confirmed that SUVmax increased with the grades of malignancy of pathological subtypes. The data revealed that FDG reflected tumour biometabolic activity. SUVmax has been shown to be positively correlated with the mitotic count of tumours in lung adenocarcinoma patients. As the size of the tumour increases, the blood supply of the tumour may be insufficient, resulting in tumour hypoxia and necrosis. However, tumour cells can increase glucose metabolism to adapt low-oxygen environment and switch anaerobic glycolysis, which give rise to SUVmax elevation. Therefore, tumour size may roughly reflect the number of tumour cells. SUVmax also is significantly correlated with tumour cell density. However, some patients with NSCLC with specific gene mutations or biomarker expressions had great benefits from targeted therapy or immunotherapy, which SUVmax values of these patients need to explore it. Reportedly, SUVmax value in patients with parietal pleural invasion was significantly higher than that of those without it. We believe that these factors are superimposed on the process of tumour.

We found that SUVmax was not as significant when tumour size was more than 3 cm. This result implied that there may be differences in the metabolic pattern of

Sun X, et al. BMJ Open 2022;12:e056804. doi:10.1136/bmjopen-2021-056804

Open access
lungs with adenocarcinoma tumour diameter with < or >3 cm. Li et al. reports demonstrated that there was a significant difference in perfusion between tumours with a diameter of <3 cm and tumours with a diameter of >3 cm. Based on the above results, we speculated that the changes in glucose metabolism patterns may be related to the blood supply of the tumour before and after the T1 stage. This may be one of the reasons why the tumour size and the SUVmax values were significantly different in <3 cm tumour size, and the difference was no longer significant in >3 cm tumour size.

VPI is one of the factors that increases the T staging of lung cancer with a diameter of <3 cm. Some meta-analyses have shown that VPI with tumour sizes less than 2 cm and 2–3 cm had a poor prognosis. Our study showed that the mean value of T2 VPI SUVmax (10.49±4.81) was higher than that of any T1x group (p<0.001). Previous studies suggested that the prognosis of T2VPI group was worse than that of T1 stage. After the T stage grouping, SUVmax value of APA subtypes in the T2VPI group was higher than that of T3 and lower than that of the T4 group.

Our data indicated that SUVmax value was closely associated with T stages, the grades of malignancy and some pathological subtypes. However, current study has following limitations: (1) SUVmax value did not tell predictive value of preoperative and estimate likelihood of recurrence in operative treatment of lung adenocarcinoma, (2) no clear relationship between SUVmax in different T stages and metastasis, (3) SUVmax did not provide correlations of those patients with minor T stages, but potentially high-grade patterns. Therefore, our future work will explore these relationships between SUVmax measurement and predictive, recurrence and metastasis roles of patients.

CONCLUSION
SUVmax values of lung adenocarcinoma in the same T stage group increase with the grades of malignancy. SUVmax value of the same histological grade or pathological subtype group increased in T1a-1c stages, but no significant differences in T2–T4 stages.

REFERENCES
1 Suzuki K, Asamura H, Kusumoto M, et al. ‘Early’ peripheral lung cancer: prognostic significance of ground glass opacity on thin-section computed tomographic scan. Ann Thorac Surg 2002;74:1635–9.
2 Sakurai H, Maeshima A, Watanabe S-Ichi, et al. Grade of stromal invasion in small adenocarcinoma of the lung: histopathological minimal invasion and prognosis. Am J Surg Pathol 2004;28:198–206.
3 Warth A, Muley T, Meister M, et al. The novel histologic international association for the study of lung Cancer/American thoracic Society/European respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438–46.
4 Xu L, Tavora F, Battafarano R, et al. Adenocarcinomas with prominent lepidic spread: retrospective review applying new classification of the American thoracic Society. J Thorac Oncol 2013;8:52–61.
5 Endoh H, Ichikawa A, Yamamoto R, et al. Prognostic impact of preoperative FDG-PET positive lymph nodes in lung cancer. Int J Clin Oncol 2021;26:87–94.
6 Suárez-Piñera M, Bedía-Sanchis J, Taus A, et al. Fdg PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. J Nucl Med Mol Imaging 2018;8:100–9.
7 Nakamura H, Saji H, Shinmyo T, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer 2015;87:28–33.
8 Shao X, Niu R, Jiang Z, et al. Role of PET/CT in management of early lung adenocarcinoma. AJR Am J Roentgenol 2020;214:437–45.
9 Yang B, Ji H, Ge Y, et al. Correlation Study of "FI T". Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Pathological Subtypes of Invasive Lung Adenocarcinoma and Prognosis. Front Oncol 2019;9:908.
10 Kadota K, Colovos C, Suzuki K, et al. Fdg-Pet SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 2012;19:3598–605.
I lung cancers.

Shiono S, Abiko M, Sato T, et al. Prognostic significance of preoperative consolidation therapy in stage I non-small cell lung cancer. *J Thorac Oncol* 2010;5:1925–30.

Vesselle H, Freeman JD, Wiens L, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contraindi cation for prognosis. *Cancer Res* 2007;67:3255–63.

Chiu C-H, Yeh Y-C, Lin K-H, et al. Histological subtypes of lung adenocarcinomas: lessons from histological subtypes. *Jpn J Clin Oncol* 2015;45:767.

Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244–85.

Nakayama H, Okumura S, Daisaki H, et al. Analysis of Prognostic Values of Various PET Metrics in Preoperative 18 F-FDG PET for Early-Stage Bronchogenic Carcinoma for Prognostication and On-Radiotherapy Significantly Increased Glycolysis Is a Predictive Factor. *J Nucl Med* 2017;58:1925–30.

Sica G, Yoshizawa A, Sima CS, et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease progression in patients: an obser vational study. *Lung Cancer Pathol* 2004;10:41–7.

Lococo F, Galeone C, Formisano D, et al. 18F-Fluorodeoxyglucose positron emission tomographic scan in solid-type p-stage-I pulmonary adenocarcinomas: what can produce false-negative results? *Eur J Cardiothorac Surg* 2017;51:eww394.

Kadota K, Colome-Céspedes C, Suzuki K, et al. Fdg-Pet SUVmax combined with ISACL/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. *Ann Surg Oncol* 2012;19:3598–605.

Veselke H, Schmidt RA, Pugsley JM, et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. *Int J Radiat Oncol Biol Phys* 1988;14:831–8.

Rajendran JD, Mankoff DA, O’Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. *Cancer Res* 2004;64:2245–52.

Sahiner I, Atasever T, Akdemir UO, et al. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer. *Rev Esp Med Nucl Imagen Mol* 2013;32:357–63.

Hsu H-H, Ko K-H, Chou Y-C, et al. SUVmax and tumor size predict surgical outcome of synchronous multiple primary lung cancers. *Medicine* 2016;95:e2351.

Kim KH, Ryu S-Y, Lee HY, et al. Evaluating the tumor biology of lung adenocarcinoma: a multimodal analysis. *Medicine* 2019;98:e18313.

van den Broek O, Hiltermann TJN, Biesma B, et al. Implementation of novel molecular biomarkers for non-small cell lung cancer in the Netherlands: how to deal with increasing complexity. *Front Oncol* 2019;9:1521.

Li Y, Yang Z-G, Chen T-W, et al. Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. *Lung Cancer* 2008;61:44–53.

Ippolito D, Capraro C, Guerra L, et al. Feasibility of perfusion CT technique integrated into conventional 18FDG-PET/CT studies in lung cancer patients: clinical staging and functional information in a single study. *Eur J Nucl Med Mol Imaging* 2013;40:156–65.

Liu Q-X, Deng X-F, Zhou D, et al. Visceral pleural invasion impacts the prognosis of non-small cell lung cancer: a meta-analysis. *Eur J Surg Oncol* 2016;42:1707–13.

Jiang L, Liang W, Shen J, et al. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis. *Chest* 2015;148:903–11.